SCHEMBL21391714

SCHEMBL21391714

Cc1ncnc2c1ccn2[C@@H]1O[C@H](C(O)c2ccc(F)c(Cl)c2)[C@@H](O)[C@H]1O

nearest known ligand 0.84

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 20/20 0.84
▸ WDR77 Q9BQA1 19/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21413921 1.00 PRMT5 (0.84) PRMT5WDR77
SCHEMBL18026204 1.00 PRMT5 (0.84) PRMT5WDR77
SCHEMBL18009778 0.92 PRMT5 (1.00) PRMT5WDR77
SCHEMBL18026115 0.92 PRMT5 (1.00) PRMT5WDR77
SCHEMBL21391696 0.91 PRMT5 (0.87) PRMT5WDR77
SCHEMBL18026196 0.91 PRMT5 (0.87) PRMT5WDR77
SCHEMBL21413920 0.91 PRMT5 (0.87) PRMT5WDR77
SCHEMBL18056013 0.89 PRMT5 (0.72) PRMT5WDR77
SCHEMBL19696633 0.88 PRMT5 (0.78) PRMT5WDR77
SCHEMBL18205102 0.88 PRMT5 (0.78) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-10-01 — — US claimed
EP-3262057-B1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2020-04-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428104-B2 Substituted nucleoside derivatives useful as anticancer agents TYMP, NME1, DPYD PRMT5 1543/4885WDR77 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback